In 2023, there were 18.7 deaths from prostate cancer per 100,000 men in the United States. This statistic shows the prostate cancer death rate in the United States from 1975 to 2023.

Legacy unique identifier: P00624

In 2023, there were around **** deaths from prostate cancer per 100,000 population in the state of Mississippi, making it the state with the highest prostate cancer death rate that year. This statistic shows the death rate from prostate cancer in the U.S. in 2023, by state.

In 2021, there were 32,563 deaths in the United States due to prostate cancer. This statistic shows the number of deaths due to prostate cancer in the United States from 1999 to 2021.

Prostate cancer incidence rates in the United States vary significantly across racial and ethnic groups, with Non-Hispanic Black men facing the highest risk. According to recent data, Non-Hispanic Black males have an incidence rate of 194.8 per 100,000 population, which is substantially higher than the overall rate of 120.2 per 100,000. This stark disparity highlights the importance of targeted screening and prevention efforts to address this health inequality. Incidence and mortality trends The burden of prostate cancer in the U.S. has grown in recent years. In 2025, approximately 313,780 men were projected to be diagnosed with prostate cancer, representing a significant increase from previous years. Despite this rising incidence, mortality rates have shown improvement. In 2022, the prostate cancer death rate was 18.7 per 100,000 men, compared to a rate of almost 39 per 100,000 in the year 1990. This decrease reflects advancements in treatment and early detection. Risk factors and survival rates Age remains a critical risk factor for prostate cancer, with men aged 65 to 84 having a 10.6 percent chance of developing the disease. However, there is encouraging news regarding survival rates. From 2014 to 2020, the five-year relative survival rate for prostate cancer patients in the U.S. was an impressive 97 percent. This high survival rate underscores the importance of early detection and the effectiveness of current treatment options.

From 2019 to 2023, around 34 percent of prostate cancer deaths in the United States were among men aged 75 to 84 years. During that period, the median age of death for prostate cancer was 79 years. This statistic shows the distribution of prostate cancer deaths in the United States between 2019 and 2023, by age.

Rate: Number of deaths due to prostate cancer per 100,000 male population.

Definition: Number of deaths per 100,000 males with malignant neoplasm (cancer) of the prostate as the underlying cause of death (ICD-10 code: C61).

Data Sources:

(1) Centers for Disease Control and Prevention, National Center for Health Statistics. Compressed Mortality File. CDC WONDER On-line Database accessed at http://wonder.cdc.gov/cmf-icd10.html

(2) Death Certificate Database, Office of Vital Statistics and Registry, New Jersey Department of Health

(3) Population Estimates, State Data Center, New Jersey Department of Labor and Workforce Development

Deaths from prostate cancer - Directly age-Standardised Rates (DSR) per 100,000 population Source: Office for National Statistics (ONS) Publisher: Information Centre (IC) - Clinical and Health Outcomes Knowledge Base Geographies: Local Authority District (LAD), Government Office Region (GOR), National, Primary Care Trust (PCT), Strategic Health Authority (SHA) Geographic coverage: England Time coverage: 2005-07, 2007 Type of data: Administrative data

This dataset contains Cancer Incidence data for Prostate Cancer(All Stages^) including: Age-Adjusted Rate, Confidence Interval, Average Annual Count, and Trend field information for US States for the average 5 year span from 2018 to 2022.Data are for males segmented age (All Ages, Ages Under 50, Ages 50 & Over, Ages Under 65, and Ages 65 & Over), with field names and aliases describing the sex and age group tabulated.For more information, visit statecancerprofiles.cancer.govData NotationsState Cancer Registries may provide more current or more local data.TrendRising when 95% confidence interval of average annual percent change is above 0.Stable when 95% confidence interval of average annual percent change includes 0.Falling when 95% confidence interval of average annual percent change is below 0. † Incidence rates (cases per 100,000 population per year) are age-adjusted to the 2000 US standard population (SEER areas use 20 age groups and NPCR areas use 19 age groups). Rates are for invasive cancer only (except for bladder cancer which is invasive and in situ) or unless otherwise specified. Rates calculated using SEER*Stat. Population counts for denominators are based on Census populations as modified by NCI. The US Population Data File is used for SEER and NPCR incidence rates.‡ Incidence Trend data come from different sources. Due to different years of data availability, most of the trends are AAPCs based on APCs but some are APCs calculated in SEER*Stat. Please refer to the source for each area for additional information.Rates and trends are computed using different standards for malignancy. For more information see malignant.^ All Stages refers to any stage. Due to changes in stage coding, Combined Summary Stage with Expanded Regional Codes (2004+) is used for data from Surveillance, Epidemiology, and End Results (SEER) databases and Merged Summary Stage is used for data from National Program of Cancer Registries databases. Due to the increased complexity with staging, other staging variables maybe used if necessary.Data Source Field Key(2) Source: National Program of Cancer Registries SEER*Stat Database - United States Department of Health and Human Services, Centers for Disease Control and Prevention (based on the 2024 submission).(7) Source: SEER November 2024 submission.

In the period 2019 to 2023, the death rate for prostate cancer among Hispanic Americans was **** per 100,000 population. This statistic shows the death rate for prostate cancer among U.S. males from 2019 to 2023, by race and ethnicity.

Dataset Description This dataset contains information on cancer deaths by country, type, and year. It includes data on 18 different types of cancer, including liver cancer, kidney cancer, larynx cancer, breast cancer, thyroid cancer, stomach cancer, bladder cancer, uterine cancer, ovarian cancer, cervical cancer, prostate cancer, pancreatic cancer, esophageal cancer, testicular cancer, nasopharynx cancer, other pharynx cancer, colon and rectum cancer, non-melanoma skin cancer, lip and oral cavity cancer, brain and nervous system cancer, tracheal, bronchus, and lung cancer, gallbladder and biliary tract cancer, malignant skin melanoma, leukemia, Hodgkin lymphoma, multiple myeloma, and other cancers.

Data Fields The dataset includes the following data fields:

• Country: The country where the cancer death occurred.
• Code: The country code for the country where the cancer death occurred.
• Year: The year in which the cancer death occurred.
• Liver cancer: The number of cancer deaths from liver cancer in the country in the year.
• Kidney cancer: The number of cancer deaths from kidney cancer in the country in the year.
• Larynx cancer: The number of cancer deaths from larynx cancer in the country in the year.
• Breast cancer: The number of cancer deaths from breast cancer in the country in the year.
• Thyroid cancer: The number of cancer deaths from thyroid cancer in the country in the year.
• Stomach cancer: The number of cancer deaths from stomach cancer in the country in the year.
• Bladder cancer: The number of cancer deaths from bladder cancer in the country in the year.
• Uterine cancer: The number of cancer deaths from uterine cancer in the country in the year.
• Ovarian cancer: The number of cancer deaths from ovarian cancer in the country in the year.
• Cervical cancer: The number of cancer deaths from cervical cancer in the country in the year.
• Prostate cancer: The number of cancer deaths from prostate cancer in the country in the year.
• Pancreatic cancer: The number of cancer deaths from pancreatic cancer in the country in the year.
• Esophageal cancer: The number of cancer deaths from esophageal cancer in the country in the year.
• Testicular cancer: The number of cancer deaths from testicular cancer in the country in the year.
• Nasopharynx cancer: The number of cancer deaths from nasopharynx cancer in the country in the year.
• Other pharynx cancer: The number of cancer deaths from other pharynx cancer in the country in the year.
• Colon and rectum cancer: The number of cancer deaths from colon and rectum cancer in the country in the year.
• Non-melanoma skin cancer: The number of cancer deaths from non-melanoma skin cancer in the country in the year.
• Lip and oral cavity cancer: The number of cancer deaths from lip and oral cavity cancer in the country in the year.
• Brain and nervous system cancer: The number of cancer deaths from brain and nervous system cancer in the country in the year.
• Tracheal, bronchus, and lung cancer: The number of cancer deaths from tracheal, bronchus, and lung cancer in the country in the year.
• Gallbladder and biliary tract cancer: The number of cancer deaths from gallbladder and biliary tract cancer in the country in the year.
• Malignant skin melanoma: The number of cancer deaths from malignant skin melanoma in the country in the year.
• Leukemia: The number of cancer deaths from leukemia in the country in the year.
• Hodgkin lymphoma: The number of cancer deaths from Hodgkin lymphoma in the country in the year.
• Multiple myeloma: The number of cancer deaths from multiple myeloma in the country in the year.
• Other cancers: The number of cancer deaths from other cancers in the country in the year.

Data Source The data in this dataset was collected from the World Health Organization (WHO). The WHO collects data on cancer deaths from countries around the world.

Usage This dataset can be used to study cancer deaths by country, type, and year. It can also be used to compare cancer death rates between different countries or over time.

https://www.googleapis.com/download/storage/v1/b/kaggle-user-content/o/inbox%2F16169071%2F98f6c6f321aad496b703685519b6df6a%2Fcancer-cells-th.jpg?generation=1694610742970317&alt=media" alt="">

To investigate the global incidence of prostate cancer with special attention to the changing age structures. Data regarding the cancer incidence and population statistics were retrieved from the International Agency for Research on Cancer in World Health Organization. Eight developing and developed jurisdictions in Asia and the Western countries were selected for global comparison. Time series were constructed based on the cancer incidence rates from 1988 to 2007. The incidence rate of the population aged ≥ 65 was adjusted by the increasing proportion of elderly population, and was defined as the “aging-adjusted incidence rate”. Cancer incidence and population were then projected to 2030. The aging-adjusted incidence rates of prostate cancer in Asia (Hong Kong, Japan and China) and the developing Western countries (Costa Rica and Croatia) had increased progressively with time. In the developed Western countries (the United States, the United Kingdom and Sweden), we observed initial increases in the aging-adjusted incidence rates of prostate cancer, which then gradually plateaued and even decreased with time. Projections showed that the aging-adjusted incidence rates of prostate cancer in Asia and the developing Western countries were expected to increase in much larger extents than the developed Western countries.

In 2025, there were an estimated 313,780 new cases of prostate cancer in the United States, as well as 35,770 deaths. That year, prostate cancer cases accounted for around 15 percent of all new cancer cases and around six percent of all deaths due to cancer. This statistic shows the number of prostate cancer cases and deaths in the United States in 2025.

This dataset contains the raw files exported from the CDC-WONDER database, and selections needed on the CDC-WONDER Multiple Causes of Death database in order to access and replicate our data and findings.

PurposeThe risk of cardiovascular disease (CVD) mortality in patients with localized prostate cancer (PCa) by risk stratification remains unclear. The aim of this study was to determine the risk of CVD death in patients with localized PCa by risk stratification.Patients and methodsPopulation-based study of 340,806 cases in the Surveillance, Epidemiology, and End Results (SEER) database diagnosed with localized PCa between 2004 and 2016. The proportion of deaths identifies the primary cause of death, the competing risk model identifies the interaction between CVD and PCa, and the standardized mortality rate (SMR) quantifies the risk of CVD death in patients with PCa.ResultsCVD-related death was the leading cause of death in patients with localized PCa, and cumulative CVD-related death also surpassed PCa almost as soon as PCa was diagnosed in the low- and intermediate-risk groups. However, in the high-risk group, CVD surpassed PCa approximately 90 months later. Patients with localized PCa have a higher risk of CVD-related death compared to the general population and the risk increases steadily with survival (SMR = 4.8, 95% CI 4.6–5.1 to SMR = 13.6, 95% CI 12.8–14.5).ConclusionsCVD-related death is a major competing risk in patients with localized PCa, and cumulative CVD mortality increases steadily with survival time and exceeds PCa in all three stratifications (low, intermediate, and high risk). Patients with localized PCa have a higher CVD-related death than the general population. Management of patients with localized PCa requires attention to both the primary cancer and CVD.

Variables included in the best fitted models for different types of cancer mortality; main variables are denoted as age (a), year (t), gender (g), region (r), deprivation (d), average age-at-diagnosis (AAD), with corresponding interactions shown as, e.g., a:t.

Years of Life Lost (YLL) as a result of death from prostate cancer - Directly age-Standardised Rates (DSR) per 100,000 population Source: Office for National Statistics (ONS) Publisher: Information Centre (IC) - Clinical and Health Outcomes Knowledge Base Geographies: Local Authority District (LAD), Government Office Region (GOR), National, Primary Care Trust (PCT), Strategic Health Authority (SHA) Geographic coverage: England Time coverage: 2005-07, 2007 Type of data: Administrative data

In 2022, there were 157 cases of prostate cancer per 100,000 population in the state of Louisiana, making it the state with the highest prostate cancer incidence rate that year. This statistic shows the incidence rate of prostate cancer in the U.S. in 2022, by state.

Number and rate of new cancer cases diagnosed annually from 1992 to the most recent diagnosis year available. Included are all invasive cancers and in situ bladder cancer with cases defined using the Surveillance, Epidemiology and End Results (SEER) Groups for Primary Site based on the World Health Organization International Classification of Diseases for Oncology, Third Edition (ICD-O-3). Random rounding of case counts to the nearest multiple of 5 is used to prevent inappropriate disclosure of health-related information.

This dataset provides cancer incidence rates for Lake County, Illinois, broken down by cancer type. The rates are expressed per 100,000 population and cover key types of cancer, including colorectal, lung, breast, prostate, and urinary system cancers. Additionally, a combined rate for all cancers is provided.

Cancer Types:

Colorectal Cancer: Cancer occurring in the colon or rectum.
Lung Cancer: Cancer forming in lung tissues, typically in cells lining air passages.
Breast Cancer: Cancer developing in breast tissues.
Prostate Cancer: Cancer occurring in the prostate gland.
Urinary System Cancer: Cancer in organs producing and discharging urine (kidneys, ureters, bladder, urethra).
All Cancer: An aggregate of all cancer types, including the above.

This dataset is a valuable resource for researchers, public health officials, and policymakers aiming to analyze cancer trends and address health disparities in the region.